公司概覽
業務類別 --
業務概覽 Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition include drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Meyers.
公司地址 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
電話號碼 +86 51269566088
傳真號碼 +86 51269566088
公司網頁 https://www.innoventbio.com
員工數量 7502
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. De-Chao Michael Yu President, Chairman of the Board and Chief Executive Officer -- 28/04/2026
 
董事會成員
董事會 職務 更新日期
Dr. Charles Leland Cooney, PhD Independent Director 28/04/2026
Dr. Stephen A. Sherwin, M.D. Independent Director 28/04/2026
Mr. Gary J. Zieziula Independent Director 28/04/2026
Dr. De-Chao Michael Yu President, Chairman of the Board and Chief Executive Officer 28/04/2026
Mr. Hao Xi Ronald Ede Director 28/04/2026
Ms. I-Yin Joyce Hsu Independent Director 28/04/2026
Mr. Shuyun Nick Chen Lead Independent Director 28/04/2026
Dr. Shun Lu Independent Director 28/04/2026
Ms. Qian Zhang Executive Director 28/04/2026
 
所屬ETF (更新日期: 07/11/2026 02:48)
代號 名稱 佔比% ▼ 持有日期
LDEMiShares® ESG MSCI EM Leaders ETF0.001%30/10/2026
CRBNiShares Low Carbon Optd MSCI ACWI ETF0.001%30/10/2026
SPGMState Street® SPDR® Ptf MSCIGlbStkMktETF0.0005%30/10/2026
JSTCAdasina Social Justice All Cp Glbl ETF0.0003%30/10/2026
MEMAMan Active Emerging Mkts Alt ETF0.0003%30/10/2026
PBEEInvesco PureBeta FTSE Emerging Mkts ETF0.0002%31/05/2023
NTSEWisdomTree Emerging Mkts Effcnt Cr ETF0.0002%30/10/2026
TEMRT. Rowe Price Emerg Mkts Eq Research ETF0.0002%31/10/2026
VEEMVanEck MSCI EM Analyst Sentiment ETF0.0002%31/10/2026
QQIInvesco Nasdaq International Inn 100 ETF0.0002%30/10/2026
WBEMWilliam Blair Emerging Markets Eq ETF0.0001%21/10/2026
FFGXFidelity Fundamental Global ex-U.S. ETF0.0001%30/10/2026
GEMQGoldman Sachs Data Enhanced EM EquityETF0.0001%30/10/2026
REMGSPDR Bloomberg SASB EM ESG Slct ETF0.0001%31/03/2023
ENHEiShares Enhanced Emerging Mkts Actv ETF0.0001%30/10/2026
AVNCAvantis All International Cor Eq ETF0.0001%30/10/2026
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%06/03/2026
AVESAvantis Emerging Markets Value ETF<0.000001%16/08/2025
CGOCalamos Global Total Return<0.000001%31/01/2026
CHWCalamos Global Dynamic Income<0.000001%31/01/2026
  1    2    3   4    5  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.